Randomized Phase III Study of Optimal Sequencing of Hormonal Therapy and Radiation in Patients with T1-T3 Prostate Cancer

Official Title

A Randomized Phase III Trial of Optimal Sequencing of Hormone Therapy and Radiation Therapy in Patients with T1-T3 Prostate Cancer


The study is designed to evaluate the optimal sequencing of radiation therapy and hormonal therapy in the treatment of patients with carcinoma of the prostate. Patients with cT1-T3N0M0 prostate cancer will be randomized to early versus delayed radiation therapy regimen in combination with 6 months of hormonal therapy.  The main objective of this trial is to assess the optimal timing of radiation therapy on various clinical outcomes. 

Trial Description

Primary Outcome

  • PSA relapse free survival

Secondary Outcome

  • Overall survival
  • Local control rate at 2 years post completion of therapy
  • Quality of Life as measured by the EORTC QLQ–C30 and PR-25 questionnaire.
  • Treatment toxicity (RTOG Toxicity Scale including Fox Chase modifications).

Interested in this trial?

Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.


Canadian Cancer Society

These resources are provided in partnership with the Canadian Cancer Society